Browse RAP1GAP2

Summary
SymbolRAP1GAP2
NameRAP1 GTPase activating protein 2
Aliases KIAA1039; GARNL4; GTPase activating RANGAP domain-like 4; GTPase activating Rap/RanGAP domain-like 4; RAP1GA ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cytoplasm, perinuclear region
Domain PF02145 Rap/ran-GAP
Function

GTPase activator for the nuclear Ras-related regulatory protein RAP-1A (KREV-1), converting it to the putatively inactive GDP-bound state.

> Gene Ontology
 
Biological Process GO:0008361 regulation of cell size
GO:0010721 negative regulation of cell development
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0031345 negative regulation of cell projection organization
GO:0032535 regulation of cellular component size
GO:0045665 negative regulation of neuron differentiation
GO:0050768 negative regulation of neurogenesis
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051961 negative regulation of nervous system development
GO:0090066 regulation of anatomical structure size
Molecular Function GO:0005096 GTPase activator activity
GO:0008047 enzyme activator activity
GO:0030695 GTPase regulator activity
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0005635 nuclear envelope
GO:0005813 centrosome
GO:0031965 nuclear membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-392517: Rap1 signalling
Summary
SymbolRAP1GAP2
NameRAP1 GTPase activating protein 2
Aliases KIAA1039; GARNL4; GTPase activating RANGAP domain-like 4; GTPase activating Rap/RanGAP domain-like 4; RAP1GA ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RAP1GAP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRAP1GAP2
NameRAP1 GTPase activating protein 2
Aliases KIAA1039; GARNL4; GTPase activating RANGAP domain-like 4; GTPase activating Rap/RanGAP domain-like 4; RAP1GA ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RAP1GAP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRAP1GAP2
NameRAP1 GTPase activating protein 2
Aliases KIAA1039; GARNL4; GTPase activating RANGAP domain-like 4; GTPase activating Rap/RanGAP domain-like 4; RAP1GA ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RAP1GAP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2030.648
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7510.328
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1990.755
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8980.0111
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.1830.412
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.550.794
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2780.551
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8950.394
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3630.745
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0650.945
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4570.73
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2130.133
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RAP1GAP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRAP1GAP2
NameRAP1 GTPase activating protein 2
Aliases KIAA1039; GARNL4; GTPase activating RANGAP domain-like 4; GTPase activating Rap/RanGAP domain-like 4; RAP1GA ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RAP1GAP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRAP1GAP2
NameRAP1 GTPase activating protein 2
Aliases KIAA1039; GARNL4; GTPase activating RANGAP domain-like 4; GTPase activating Rap/RanGAP domain-like 4; RAP1GA ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RAP1GAP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RAP1GAP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRAP1GAP2
NameRAP1 GTPase activating protein 2
Aliases KIAA1039; GARNL4; GTPase activating RANGAP domain-like 4; GTPase activating Rap/RanGAP domain-like 4; RAP1GA ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RAP1GAP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRAP1GAP2
NameRAP1 GTPase activating protein 2
Aliases KIAA1039; GARNL4; GTPase activating RANGAP domain-like 4; GTPase activating Rap/RanGAP domain-like 4; RAP1GA ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RAP1GAP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRAP1GAP2
NameRAP1 GTPase activating protein 2
Aliases KIAA1039; GARNL4; GTPase activating RANGAP domain-like 4; GTPase activating Rap/RanGAP domain-like 4; RAP1GA ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RAP1GAP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRAP1GAP2
NameRAP1 GTPase activating protein 2
Aliases KIAA1039; GARNL4; GTPase activating RANGAP domain-like 4; GTPase activating Rap/RanGAP domain-like 4; RAP1GA ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RAP1GAP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.